Sarepta Therapeutics' (SRPT +3.4%) Eteplirsen treatment for Duchenne muscular dystrophy demonstrates stability on pulmonary function tests through 120 Weeks in a Phase IIb Study of twelve boys aged 7-13 years.
In the age group tested, pulmonary function would be expected to drop over the analysis period, says Sarepta's Edward Kaye. The results "provide early evidence towards achieving a key treatment goal, the delay or avoidance of pulmonary ventilation assistance in DMD patients."
The results add to data showing a general stabilization of walking ability in Eteplirsen-treated patients. (PR)